Evidence map›Paper›PMID 16940541›Full record

ArticleJournal of virology2006

Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Lisa M Sedger, Sarah R Osvath, Xiao-Ming Xu, Grace Li, Francis K-M Chan, John W Barrett, Grant McFadden

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. TNF Decoy Receptors Encoded by Poxviruses.Pathogens (Basel, Switzerland) · 2021
    Review
  3. Article
  4. Poxviral Strategies to Overcome Host Cell Apoptosis.Pathogens (Basel, Switzerland) · 2020
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. A survey of host range genes in poxvirus genomes.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2013
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Lisa M SedgerWestmead Millennium Institute, Westmead, NSW 2145, Australia. lisa_sedger@wmi.usyd.edu.au
Sarah R Osvath
Xiao-Ming Xu
Grace Li
Francis K-M Chan
John W Barrett
Grant McFadden
Western University · CAWestmead Institute · AUUniversity of Massachusetts Chan Medical School · USUniversity of Sydney · AU

Funding

Role of Programmed Necrosis in Immune ResponsesR21AI065877 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CHAN, FRANCIS KA-MING · 2005 to 2006
$441k
NIAID NIH HHS AI 065877NIAID NIH HHS R21 AI065877
6 · The paper itself

Abstract

The poxvirus tumor necrosis factor receptor (TNFR) homologue T2 has immunomodulatory properties; secreted myxoma virus T2 (M-T2) protein binds and inhibits rabbit TNF-alpha, while intracellular M-T2 blocks virus-induced lymphocyte apoptosis. Here, we define the antiapoptotic function as inhibition of TNFR-mediated death via a highly conserved viral preligand assembly domain (vPLAD). Jurkat cell lines constitutively expressing M-T2 were generated and shown to be resistant to UV irradiation-, etoposide-, and cycloheximide-induced death. These cells were also resistant to human TNF-alpha, but M-T2 expression did not alter surface expression levels of TNFRs. Previous studies indicated that T2's antiapoptotic function was conferred by the N-terminal region of the protein, and further examination of this region revealed a highly conserved N-terminal vPLAD, which is present in all poxvirus T2-like molecules. In cellular TNFRs and TNF-alpha-related apoptosis-inducing ligand (TRAIL) receptors (TRAILRs), PLAD controls receptor signaling competency prior to ligand binding. Here, we show that M-T2 potently inhibits TNFR1-induced death in a manner requiring the M-T2 vPLAD. Furthermore, we demonstrate that M-T2 physically associates with and colocalizes with human TNFRs but does not prevent human TNF-alpha binding to cellular receptors. Thus, M-T2 vPLAD is a species-nonspecific dominant-negative inhibitor of cellular TNFR1 function. Given that the PLAD is conserved in all known poxvirus T2-like molecules, we predict that it plays an important function in each of these proteins. Moreover, that the vPLAD confers an important antiapoptotic function confirms this domain as a potential target in the development of the next generation of TNF-alpha/TNFR therapeutics.

Indexed as

ApoptosisAmino Acid SequenceAnimalsApoptosis Regulatory ProteinsConserved SequenceHumansLymphocytesMembrane GlycoproteinsMolecular Sequence DataPoxviridaeProtein Structure, TertiaryRabbitsReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type ISequence Homology, Amino AcidTNF-Related Apoptosis-Inducing LigandApoptosis Regulatory ProteinsMembrane GlycoproteinsReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type ITNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID16940541
PMCPMC1563942
OpenAlexW2134461906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.